Marvelon

Desogestrel and Ethinylestradiol, the active ingredients in Marvelon, are a combined oral contraceptive presented as 0.15 mg/0.03 mg tablets for oral use. The formulation works by suppressing ovulation and altering cervical mucus and the endometrial lining, delivering reliable prevention of pregnancy for women of reproductive age seeking effective family‑planning options.

GNH USA supplies Marvelon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets.

Marvelon, a combined oral contraceptive, is used to prevent pregnancy by modulating hormonal regulation of the menstrual cycle. - Prevention of pregnancy: provides reliable contraceptive protection for women of childbearing age. - Family planning: enables planned spacing of pregnancies according to personal reproductive goals. - Menstrual cycle regulation: may help achieve more predictable bleeding patterns and reduce dysmenorrhea.

Oral contraceptives such as Marvelon may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild stomach upset, especially during the initial cycles. - Breast tenderness: temporary swelling or discomfort of the breasts. - Headache: occasional mild to moderate headaches. - Spotting between periods: irregular light bleeding. - Weight gain: slight increase in body weight or fluid retention. - Mood changes: mild fluctuations in mood or emotional state.

Serious or Rare Side Effects: - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Severe hypertension: sudden high blood pressure requiring medical attention. - Hepatic adenoma: benign liver tumor development. - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Visual disturbances: sudden loss of vision or eye pain. - Stroke: rare cerebrovascular accident.

Before prescribing Marvelon, clinicians should evaluate patient history and consider specific safety measures. - Assess thrombotic risk: avoid use in women with a history of blood clots or clotting disorders. - Review cardiovascular status: contraindicated in uncontrolled hypertension or significant heart disease. - Evaluate liver function: caution in patients with active liver disease or severe hepatic impairment. - Consider smoking status: smoking >15 cigarettes per day increases cardiovascular risk, especially in women over 35. - Discuss medication adherence: missed tablets reduce efficacy and increase pregnancy risk. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and direct sunlight.

Marvelon can interact with several medicines, altering its contraceptive effectiveness or increasing adverse effect risk.

Major Interactions (Avoid): - Enzyme‑inducing antiepileptics (e.g., carbamazepine, phenytoin): markedly reduce hormone levels, risking contraceptive failure. - Rifampin and other strong inducers: decrease oral contraceptive efficacy. - Protease inhibitors (e.g., ritonavir): may increase hormone concentrations, leading to heightened side‑effect risk.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., tetracycline, metronidazole): may slightly lower contraceptive effectiveness. - St John’s wort: herbal inducer that can reduce plasma hormone levels. - Antifungal agents (e.g., fluconazole): can increase estrogen exposure, potentially enhancing side effects.